Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USCP119 is a botanical combination product consisting of a mixed extract of *Salvia miltiorrhiza* (Danshen) and *Paeonia lactiflora* (Peony). It is being investigated for its hypolipidemic and metabolic-regulating properties. In preclinical models, USCP119 has demonstrated the ability to reduce serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol, while also decreasing hepatic lipid accumulation and epididymal fat. Its mechanism of action involves the activation of the AMPK signaling pathway, which improves lipid metabolism and insulin sensitivity. It is primarily positioned as a potential dietary supplement or nutraceutical for the management of high-fat diet-induced hyperlipidemia and related metabolic disturbances.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on USCP119.